M. Santoscoy

Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial.

Samit R. Joshi, G. McComsey, Samir K. Gupta, 2016, The lancet. HIV.

A Phase 2b randomised, controlled, partially blinded trial of the HIV Nucleoside Reverse Transcriptase Inhibitor BMS-986001 (AI467003): Weeks 24 and 48 Efficacy, Safety, Bone and Metabolic Results

Samit R. Joshi, G. McComsey, Samir K. Gupta, 2016 .

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

K. Ruxrungtham, E. Katabira, D. Steyn, 2010, AIDS.